RE: Inflection point29 Dec 2025 12:11
Who cares what I think?
I was not being 'dismissive', I was seeking clarification.
The major differnce between now and when AVA6000 started is that we now have a savvy team that is experienced in clinical development. Yes, the dipeptide is specific for FAP, but AVA6103 will be a completely new and thus unknown molecule in the human body, so Avacta and the FDA will be cautious to begin with.
AVA6103 will be angled to target indications from the start, so a lot earlier than AVA6000 was, and hence will acquire more useful efficacy data sooner, but there are still unknowns that require a precautionary approach though, namely a safe starting dose (which CC talked about in that Peel Hunt interview). What that dose is, how big the escalation steps are - particularly the first one if te initial dosing is shown to be very safe, how long each cohort will take and how many cohorts get dosed will determine the end point, which is just as important as the starting point.